Our Goal to Help the Epilepsy Community is Personal
When his son had a seizure at the kitchen table in 2014, it changed Greg Mayes’ life. After hearing his teenage son’s epilepsy diagnosis, he was dismayed to learn that when a seizure strikes, there’s nothing that you can do except wait out what feel like the longest minutes of your life.
In 2016, Dr. Jacqueline French of NYU Langone Comprehensive Epilepsy Center told Mayes about Staccato Alprazolam, an easy-to-use, hand-held inhaler in a phase 2a clinical trial with the potential to be the first rescue treatment of its kind that could terminate the current seizure. A seasoned pharmaceutical executive with decades of experience in the industry, Mayes realized that he had the background and know-how it took to make Staccato Alprazolam a reality for the epilepsy community.
Working with leading epileptologists, neurologists, and healthcare executives, Mayes founded Engage Therapeutics with the goal of successfully completing the phase 2b clinical trial required for FDA approval and ultimately bringing the epilepsy community its first viable rescue treatment to terminate a seizure.
Our Mission to Develop Staccato Alprazolam
In 2017, Engage Therapeutics entered into an exclusive license and supply agreement with Alexza Pharmaceuticals to advance Staccato Alprazolam into phase 2b development as a treatment to stop seizure activity. The clinical trial began in 2018 in study sites across the United States as part of the process required to gain FDA approval and bring the product to market.
The phase 2b clinical trial aims to assess the efficacy and safety of Staccato Alprazolam in treating naturally-occurring seizures. We are recruiting patients across the country with a diagnosis of focal or generalized epilepsy who are willing to participate in a paid, eight-week clinical trial, including up to eight days in an inpatient facility.